Skip to main content

Articles | February 2, 2017

Law360 republished the Fried Frank M&A Briefing titled “SEC Fine To Be Paid By Allergan Underscores Obligation to Disclose Negotiations With White Knight Following an Unsolicited Tender Offer.” The article focuses on Allergan’s agreement with the SEC to admit to securities law violations and pay a $15 million fine for disclosure violations relating to its Schedule 14D-9 filed in response to the unsolicited tender offer for Allergan’s shares by Valeant Pharmaceuticals International plc in 2014.

Click here to read the full article.

This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.